Asthma
Conditions
Keywords
DIFFICULT TO CONTROL ASTHMA, OMALIZUMABE
Brief summary
The purpose of this study is do describe the experience in the use of omalizumabe, in a real life scenario, in uncontrolled severe asthmatic patients attended in specialist outpatient clinics, and its efficacy and safety. The efficacy of omalizumab in the population observed will be evaluated as reduction of uncontrolled asthma related events, i.e. exacerbations, emergency dept. visits, hospitalization and asthma-related treatment (decrease of asthma medication).
Detailed description
Omalizumab is indicated in children over 6 years of age, with diagnosis of difficult to control asthma, presenting a component of atopy demonstrated preferably positive skin tests (prick test) or in vitro reactivity (rast) allergens common inhalants. Patients must also present the total serum IgE levels between 30 and 700UI/mL. Children until 12 years the IgE level is between 30 and 300 IU/ml.
Interventions
None listed
Sponsors
Fiks, Iara Nely, M.D.
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Patients on optimal asthma treatment, good compliance and no response to treatment according to asthma consensus (GINA/NAEEP and the Latinamerican Consensus for Difficult to treat Asthma)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of asthma hospitalization | ONE YEAR Of Omalizumab USE |
Secondary
| Measure | Time frame |
|---|---|
| Decrease the doses of oral steroids | ONE YEAR Of Omalizumab USE |
Countries
Brazil
Outcome results
None listed